



Multidrug Therapies Containing Monoclonal Antibodies for Multiple Myeloma 2024

Guest Editor:

Dr. Massimo Offidani

AOU delle Marche, 60126 Torrette
(AN), Italy

Deadline for manuscript
submissions:

23 September 2024

Message from the Guest Editor

Dear Colleagues,

Treatment of multiple myeloma (MM) continues to evolve, and immunotherapy has now entered its therapeutic armamentarium. In particular, monoclonal antibodies (MoAbs), such as elotuzumab, daratumumab, and isatuximab in combinations with proteasome inhibitors (PI) and immunomodulatory agents (IMiDs), successfully used for relapsed–relapsed MM.

Elotuzumab in combination with lenalidomide and dexamethasone (Rd), and subsequently, daratumumab with Rd and with bortezomib and dexamethasone (Vd) were the first to be approved for the treatment of relapsed–refractory MM (rrMM).

The new frontier of immunotherapy of MM includes bispecific and conjugated MoAbs, a very promising active area of experimental trials for rrMM patients in which preliminary results are rather favorable. It can be argued that passive and active immunotherapy will make MM a chronic disease or will cure an increasing fraction of MM patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com